Q.01

What do MHRA inspectors look for during GMP inspections?

MHRA inspectors check a site against the EU GMP Guide (EudraLex Volume 4), which the UK recognises. In MHRA's own published deficiency data, the quality system is the area cited most: root-cause analysis and CAPA for deviations, documentation and record integrity, then materials and contamination control, qualification and validation, and sterile manufacturing. Chapter 1 (Pharmaceutical Quality System) led every year of the 2017-2019 trend analysis.

How an inspection runs (GOV.UK, GMP and GDP guidance)

  • Activities: inspectors interview staff, review documents and visit the site. They may visit manufacturing, QC laboratories, storage (including temperature monitoring), returns, purchasing and sales, and transport arrangements.
  • Inspection types:
    • Routine inspections, prioritised by the site's risk rating. That rating draws on compliance reports, inspection history and organisational changes.
    • Product-related inspections tied to UK marketing authorisation applications.
    • Triggered inspections, for example after a whistleblower report, with little or no advance notice.
  • Grading of deficiencies:
    • Critical: a deficiency that "has produced or significantly risks producing a product which is harmful to humans".
    • Major: includes a major deviation from GMP or from the licence terms, a failure of batch release or of the QP's legal duties, or several "other" deficiencies that add up to a major.
    • Other: a departure from GMP that is not critical or major.
  • Afterwards: the company gets a post-inspection letter and must reply with its corrective actions. Critical findings can go to the Inspection Action Group, which can refuse or suspend a licence.

What gets cited most (MHRA official statistics, GMP sites)

20182019
Inspections in the data286258
Sites with at least one Critical1514
Most-cited areas, in orderCh 1, Ch 4, Ch 5, Annex 15, Ch 3, Annex 1same order

Sources: 2018 [1], 2019 [2].

MHRA's 2019 report ranks these as the top cited references: C1.4(xiv), C1.8(vii), C4.8, C4.3, C1.4(viii), C4.1, C1.4(xiii), C4.2, the Chapter 4 Principle and C1.6 [3]. C1.4(xiv) also topped the references behind Critical findings [4]. What those clauses require:

  1. Root cause and CAPA.
    • C1.4(xiv): investigations need "an appropriate level of root cause analysis". A conclusion of human error "should be justified", and the effectiveness of CAPAs "should be monitored and assessed" [5].
    • C1.8(vii): significant deviations must be "fully recorded, investigated" [6].
    • Back in 2013, MHRA said "investigation of anomalies" had been the most cited deficiency for five years running [7].
  2. State of control, change control and management review.
    • C1.4(viii) covers monitoring and a state of control; C1.4(xii) and (xiii) cover evaluating changes before and after they are made [5].
    • C1.6 requires periodic management review with senior management involved [8].
    • MHRA examples include management review minutes that called environmental monitoring "satisfactory" despite an obvious adverse trend [9], and PQRs months overdue [10].
  3. Documentation and data integrity.
    • C4.8: records made "at the time each action is taken" [11].
    • C4.1: controls for hybrid and electronic records "throughout the retention period" [12].
    • Findings include entries completed before the step was done and batch-record pages photocopied without control [13][14].
    • Under Annex 11 (computerised systems), findings include audit trails not enabled, analysts able to delete data, and system clocks users could change [15][16]. The 2013 rise in Critical findings was linked to data integrity [17].
  4. Materials, suppliers and contamination (Chapter 5).
    • Examples: weak supplier qualification, unmonitored receiving temperatures, and sampling that did not represent the bulk material [18].
    • C5.10 (protecting product from contamination at every stage) was among the 2019 Critical references [19].
  5. Qualification and validation (Annex 15). Examples: no user requirement specification and no change control for a site acquisition; requalification actions on a water system that were never closed out [20].
  6. Sterile manufacturing (Annex 1).
    • Examples: poor gowning, sterile gloves touched, needles contacted by RABS gloves [21][22].
    • Also aseptic work continuing despite repeated microbial failures in the critical zone, and media fills never validated [23].
  7. Resourcing and training.
    • C2.1 requires senior management to provide adequate resources [24].
    • C2.11 requires training whose practical effectiveness is "periodically assessed" [25].
  8. Repeat findings. MHRA flags sites where new deficiencies resemble earlier ones. It reads this as a quality system that fixes individual findings instead of the underlying system [26].

MHRA publishes this data so companies can benchmark themselves in their own self-inspections [27].

The newest itemised data I found is 2019, so the rankings above may not reflect current inspection priorities. In the 2019 file, non-UK sites appear only as "Rest of the World".

Approach: I used MHRA's GMP inspection deficiency statistics (2018 and 2019 itemised data, and the 2010-2016 and 2019 trend reports), the EU GMP Guide (EudraLex Volume 4) for the clause wording, and MHRA's GOV.UK GMP/GDP guidance page for the inspection process and grading.

Q.02

How are inspection deficiencies graded?

MHRA grades every GMP and GDP inspection deficiency as Critical, Major or Other. A finding is graded Critical first if it qualifies. Major covers non-critical deficiencies that meet set criteria. Other covers everything that is neither. The definitions below are quoted from MHRA's GOV.UK guidance on good manufacturing practice and good distribution practice.

Critical

  • "A deficiency which has produced or significantly risks producing a product which is harmful to humans or veterinary patients or which could result in a harmful residue in a food-producing animal."
  • For GDP: "Any departure from good distribution practice that results in a significant risk to patients." This "includes an activity which increases the risk of counterfeit medicines reaching patients."

Major: "a non-critical deficiency" that meets any one of these:

  • it "has or may produce a product that does not comply with its marketing authorisation";
  • it "indicates a major deviation from GMP or GDP or from the terms of the manufacturer licence or wholesale licence";
  • it "indicates a failure to carry out satisfactory batch release procedures", or a failure of the QP or RP "to fulfil their legal duties";
  • it is "a combination of several 'other' deficiencies which on their own may not be major but together may represent a major deficiency and should be explained and reported as such".

Other: "A deficiency which cannot be classified as either critical or major, or there is not enough information to classify it as critical or major, but which indicates a departure from good manufacturing and distribution practice."

So "Other" also covers findings where inspectors don't have enough information to grade higher. And a group of related minor findings can be raised together as a single Major.

What happens after grading. After the closing meeting, the company gets a letter listing the deficiencies. It must reply by email with its proposed corrective actions and completion dates. Inspectors then decide whether the reply is satisfactory. If it is accepted, the company receives its certificate and the inspection report. If it is not, the case may go into compliance escalation (same GOV.UK page).

How often each grade is used. MHRA's deficiency statistics report findings in these same three classes. In 2013, 630 GMP inspections raised 29 Critical and 403 Major deficiencies. 3.0% of inspections had at least one Critical and 31.6% had at least one Major. The most on one site was 3 Criticals or 7 Majors [28]. That year's rise in Criticals per inspection was linked to data integrity findings [17].

Approach: I searched MHRA's GMP and GDP inspection deficiency statistics, which use the three grades but don't define them. I took the definitions and post-inspection steps from MHRA's GOV.UK GMP/GDP guidance page.

Q.03

Which deficiencies are most common in MHRA inspection data?

Root-cause investigation of deviations and CAPA, EU GMP Chapter 1 clause 1.4(xiv), is the single most cited deficiency in MHRA's GMP inspection data. It ranked first in 2017, 2018 and 2019, and was also the top clause behind Critical findings. After it come deviation recording and investigation (C1.8(vii)), state of control (C1.4(viii)), documentation (C4.8, C4.3, C4.1, C4.2), change control (C1.4(xii)/(xiii)) and management review (C1.6). Earlier years show the same picture, with "Investigation of anomalies" the top category every year from 2009 to 2013.

MHRA's own 2019 ranking (year-on-year slide) [3]

Rank201720182019
11.41.4C1.4(xiv)
21.81.8C1.8(vii)
34.84.8C4.8
44.14.1C4.3
54.24.2C1.4(viii)
64.31.1C4.1
71.14.3C1.4(xiii)
83.412.11C4.2
93.193.19C4 Principle
105.13.41C1.6

MHRA says it started trending down to the individual sub-part of each clause in 2019. That is why 2017-2018 show whole clauses only. The chart elsewhere in the same deck has C1.4(xii) at 7th instead of C1.4(xiii) [29].

My count from the itemised 2018 and 2019 workbooks (one cited reference per line)

  • Most cited clauses.
    • 2018: C1.4(xiv) 210 [30], C1.8(vii) 139 [31], C1.4(viii) 114 [32], C4.8 112 [33], C1.4(xii) 99 [34], C4.1 95 [35].
    • 2019: C1.4(xiv) 194 [36], C1.8(vii) 107 [37], C1.4(viii) 95 [38], C4.8 84 [39], C4.3 83 [40].
    • My order differs slightly from MHRA's slide (for example, I have C1.4(viii) third in 2019). MHRA does not say how it counted.
  • Chapters and annexes, same order both years: Chapter 1, then Chapter 4, Chapter 5, Annex 15, Chapter 3 and Annex 1. In 2019 Annex 11 (computerised systems) climbed to 8th.
  • Major findings are led by C1.4(xiv) (107 in 2018, 94 in 2019), then C1.8(vii), C1.4(viii) and C1.4(xii). Supplier control (C5.20) and C1.5 also appear among the leading Major references.
  • Critical findings. MHRA's 2019 top 10 for Criticals is C1.4(xiv), C1.4(viii), C1.8(vii), A1.18, 50.1(IAG), A1.64, C2.1, C1.4(vi), A1.20 and c5.10, with C1.4(xii) and C1.4(vii) also on the chart [4]. Annex 1 (sterile) clauses feature heavily here.

Earlier trend reports (grouped categories, not clauses)

  • 2009-2013: "Investigation of anomalies" ranked 1st in every year. Quality management, CAPA, supplier and contractor audit, change control and documentation of procedures, PSF and technical agreements were consistently in the top group. Contamination (chemical/physical, or potential for) rose sharply in 2012-2013 [41]. MHRA called it "the most cited inspection deficiency over the last five years" [7].

  • 2011-12 top 10:

    1. Investigation of anomalies
    2. Change control
    3. CAPA
    4. Complaints and recall
    5. Quality management
    6. Supplier/contractor audit
    7. Contamination potential
    8. Documentation (PSF, procedures, technical agreements)
    9. Manufacturing documentation
    10. Process validation

    [42]

  • 2015:

    1. Quality System
    2. Complaints and Recall
    3. Documentation
    4. Quality Control
    5. Computerised Systems
    6. Production
    7. Premises & Equipment
    8. Validation
    9. Personnel
    10. Materials Management

    [43]

  • 2016:

    1. Quality System (38 Critical, 449 Major, 772 Other)
    2. Sterility Assurance (34 / 190 / 162)
    3. Production
    4. Complaints and Recall
    5. Qualification/Validation
    6. Premises & Equipment
    7. Computerised Systems
    8. Personnel
    9. Documentation
    10. Quality Control

    [44]

GDP (wholesale distribution), 2016

  • What the report covers: only Major findings, from a sample of 148 of the 1,428 GDP inspections that year [45].
  • No ranking available: the per-reference counts are in charts whose values I could not read, so I can't give a GDP ranking.
  • Typical examples MHRA gives:
    • Deviations closed before CAPA was done, and management reviews that left out deviations [46].
    • Inadequate temperature mapping, and uncalibrated thermometers [47][48].
    • Fabricated temperature readings [49].
    • Supplier GDP status not verified [50].
    • No audit of contract acceptors [51].

The newest itemised data is 2019, so these rankings are not current.

Approach: I used MHRA's GMP and GDP inspection deficiency statistics: the 2018 and 2019 itemised GMP workbooks (which I tallied myself), MHRA's 2019 top-10 deck, the 2010-2016 trend reports and the 2016 GDP report.

Q.04